Contract 75D30124D19011
Moderna Us, Inc. · Department Of Health And Human Services · July 31, 2024
Moderna Us, Inc. was awarded a federal contract by Department Of Health And Human Services (Centers For Disease Control And Prevention) on July 31, 2024 for $105.93 million of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on December 3, 2025. If all options are exercised, the contract could reach $481.10 million.
Contract details
- PIID
- 75D30124D19011
- Award type
- —
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- July 31, 2024
- Latest action
- December 3, 2025
Description
COVID-19 PEDIATRIC VACCINES
Modification timeline
-
December 3, 2025Mod P00005 · Other Administrative Action$105.94M
-
September 6, 2024Mod P00003 · Funding Only Action$143.25M
-
August 22, 2024Mod P00002 · Other Administrative Action$143.18M
-
July 31, 2024Mod P00001 · Funding Only Action$143.18M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Merck Sharp & Dohme Llc | Department Of Health And Human Services | March 27, 2026 | $361.34M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75D30124D19011?
Contract 75D30124D19011 is a federal contract awarded to Moderna Us, Inc. by Department Of Health And Human Services on July 31, 2024 for $105.93 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 3 times since the base award.
Who won contract 75D30124D19011?
Moderna Us, Inc. won contract 75D30124D19011 from Department Of Health And Human Services.
How much is contract 75D30124D19011 worth?
Contract 75D30124D19011 has obligated $105.93 million to date, with a total potential value of $481.10 million if all options are exercised.